Late complications after hematopoietic stem cell transplant in adult patients
|
|
- Clare Richardson
- 6 years ago
- Views:
Transcription
1 Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France
2 Synopsis H S C T Allogeneic HSCT activity in Europe Allogeneic total HSCT RIC HSCT Plan of this overview Why an educational talk on LE? Non malignant Complications (selected) Secondary malignancies Quality of life issues
3 EHA 2011 Educational Book Expert Rev. Hematol. 2009; 2(5): Late complications after hematopoietic stem cell transplantation
4 Why an educational talk on LE? 1. Increasing numbers of transplants Transplant activity in Europe Bone Marrow Transplantation (2011) 46,
5 Why an educational talk on LE? 2. Improved results N Engl J Med 2010;363:
6 Why an educational talk on LE? 3. But still faced with increased late mortality! J Clin Oncol Mortality ratios cohort of 7,984 long term survivors
7 Why an educational talk on LE? 4. And some morbidity in long term! For some patients
8 Non malignant LE Endocrine Bone & joints Ophthalmological Respiratory. Cardiac & vascular Socié G. et al. Blood. 2003; 101: Tichelli A et al. Expert Rev Hematol :
9 Non malignant LE Risk factors Chemotherapy TBI GVHD Virus Immunosuppressive therapy Immunodeficiency
10 Nonmalignant late effects are heterogeneous in nature and intensity ity Endocrine dysfunction Thyroid function Gonadal, fertility Growth and development Skeletal disorders Ocular problems Respiratory tract problems Restrictive lung disease Obstructive lung disease Salivary function and dental problems Liver complication Vascular complication Socié G. et al. Blood. 2003; 101: Any organ or tissue can be the target of late effects after allogeneic stem cell transplantation
11 Irradiation of the thyroid gland region is associated with increased risk of hypothyroidism Hypo-, hyperthyroidism Incidence thyroid dysfunction Biological in 40% Clinical in 5%-25% Median time for appearance Median time 5 years Irradiation, the main risk factor Single dose (50%) Fractionated (15%) BuCy (11%) Younger age Al Fiar FZ et al. Bone Marrow Transplant. 1997;19: Hiroyuki Ishiguro et al. JClinEndocrinolMetab. 2004; 89:
12 Skeletal disorders Osteopenia/osteoporosis Reduced bone mass and increased susceptibility of bone fractures Low bone density (50%) Osteopenia (30%) Osteoporosis (10%) Risk factors TBI for conditioning Chronic GvHD Steroids, CSA and tacrolimus Prolonged inactivity Estrogen deficiency Avascular necrosis of bone Incidence rates 5-15% Leading symptom: pain Most affected joint: hip Risk factors Steroids and TBI Early detection by MRI Socié G. et al. Br J Haematol. 1997;97:
13 Non malignant LE Increasingly recognized Obstructive lung Diseases Osteonecrosis Allo-HSCT: unrelated Abnormal PFT (%) Allo-HSCT: related Auto-HSCT Abnormal PFT (%) Campell et al. Cancer. 2009; 115: Savani B. et al. BBMT. 2006; 12:
14 Non malignant LE Changing incidences Belkacemi Y. et al. Int J Radiat Oncol Biol Phys. 1998; 41, Tichelli et al. Ann Int Med ;
15 Bhatia S. et al. Blood 2005; 105: Bhatia S. et al. Blood. 2007;110: Median age at HSCT Median follow-up Total deaths Primary disease cgvhd Infection without GVHD Undetermined cause Non malignant LE New complications on the very long term Cardio vascular LE Autologous HCT n= (0.6-69) 7.6 ( ) (56%) (1%) Allogeneic HCT n= (0.2-71) 9.5 (2-28.4) (29%) 53 (22%) 27 (11%) Treatment related deaths 108 (43%) 61 (25%) Secondary malignancy Pulmonary complications 62 (25%) 35 (13.5%) (7%) 12 (5%) Cardiac toxicity 5 (2%) 8 (3%)
16 Cardio vascular LE Non malignant LE Complications types Dose of anthracycline in pediatric cancer survivors Myocarditis Pericarditis Congestive heart failure Coronary disease
17 Non malignant LE Cardio vascular LE Prospective 119 children Left ventricular function (US) Résults > cumulative incidence < ventricular function TBI+ anthracyclines 26% No TBI, no anthracyclines: 2% At 5 years 13% of kids had asymptomatic decreased functioning Uderzo C. et al. BMT. 2007; 39:
18 Characteristics Cardio vascular LE Allogeneic HSCT n= 265 Autologous HSCT n= 145 Non malignant LE P-value Male, n (%) 145 (55%) 87 (60%) 0.3 Median age at HSCT 27 (2-60) 44.5 (2-69) <0.001 Median age at last follow-up 39 (6-66) 49 (3-72) <0.001 Median follow-up since HSCT 9 (2-24) 5 (2-16) <0.001 Cardiovascular risk factors before HSCT Tichelli A. et al. Blood. 2007; 110:
19 Cardio vascular LE Non malignant LE Allo HSCT 265 Auto HSCT 145 Arterial events 18 (6.8%) 3 (2.1%) Territories involved 23 3 Age at HSCT Age at vascular event 39 (19-59) 48 (29-62) 50 (36-59) 54 (38-60) Time interval to event (y) 9 (2-21) 21) 1.3 (0.7-4)
20 Cardio vascular LE Non malignant LE Tichelli A. et al. Blood. 2007; 110:
21 Cardio vascular LE Allogeneic HSCT Autologous HSCT Siblings Non malignant LE Diabetes Hypertension Arterial Disease MI Stroke Allo 3.6 ( ) 2.1 ( ) 1.2 ( ) 1.2 ( ) 3.5 ( ) Auto 2.0 ( ) 0.9 ( ) 0.4 ( ) 0.4 ( ) 2.6 ( ) Sibling Adjusted for age, age at transplant, and sex Baker S. et al. Blood, 2007; 109:
22 Non malignant LE Majhail et al, for the EBMT/CIBMTR/ASBMT. Biol Blood Marrow Transplant Blone Marrow Transplant 2012 International Recommended Screening 2012
23 Non malignant LE High priority! Cumulative Incidence of Chronic Health Conditions among 10,397 Adult Survivors of Pediatric Cancer N Engl J Med 2006;355:
24 Second malignancies 2008 Update Kolb HJ. Ann Intern Med. 1999;131: N=1036; allogeneic SCT, survivor > 5 years Incidence SC 3.5% - 10y 12.8% at 15 y 3.8 X general population
25 Second malignancies N=28874 Allogeneic SCT SC x 2 (O/E = 2.1) 3-X in patients followed more than 15 years. 15% 12% Cumulative Incidence Upper Confidence Limit Lower Confidence Limit 9% 6% 3% 0% Rizzo, J. D. et al. Blood 2009;113:
26 Second malignancies SC 4318 patients Bu-Cy ; AML CR1 & CML CP1. Incidence at 10 years; 1.2% AML & 2.4% CML O/E = 1.4 Not only TBI! Blood ; 2010
27 Second malignancies Cancers in very long term survivors Probability of Secondary Breast Cancer All cohort Years after HSCT 0.11 EBMT/Seattle 52 Breast cancers / 3337 survivors: incidence = 4.7% at 20 years. Age at transplant: 32.9 years ( ) No TBI Interval SCT/cancer : 12.5 years O/E: 1.4 (95%CI, 1.1,1.8)
28 Second malignancies Thyroid Cancer Age +++: RR, age 0-10 y. & years Cohen A et al. JCO 2007;25:
29 immediate survival and early relapse Organ complications reproductive status and pregnancy outcome Health status after transplant performance and social activity Quality of life fatigue syndrome Resetting life track ?
30 Quality of life QOL is a subjective perception of social emotional physical well being Gap between patients expectation of health and his experience of it perception of QOL varies between individuals changes over time In the same clinical condition patients with different expectations will report different quality of life
31 Quality of life Fatigue appears as one of the most common and distressing symptoms reported cross-sectional studies 50-75% have moderate to severe fatigue 3years after HSCT longitudinal study (43 and 62 months post transplant) no significant changes at 10 years after transplant, fatigue still the second most problematic concern
32 Sexual dysfunction is one of the most prevalent and persistent long-term problem after allogeneic SCT Quality of life 4.0 Sexual Function Mean Score + se Males: Pre-6mo. P=.001 Males: 6mo.-2yrs P=.001 Females: 6mo.-5yrs P=.17 Females: Pre-6mo. P=.003 Male Controls Male Pt-Control: P=.01 Male Survivors Female Controls Female Pt-Control: P=.03 Female Survivors Years after Transplant Syrjala et al. Blood, 2007
33 immediate survival and early relapse Organ complications reproductive status and pregnancy outcome Health status after transplant performance and social activity Quality of life fatigue syndrome Resetting life track counseling
Late effects, health status and quality of life after hemopoietic stem cell
Late effects, health status and quality of life after hemopoietic stem cell transplantation (HSCT) THE 13th ESH-EBMT TRAINING COURSE ON BLOOD AND MARROW TRANSPLANTATION EBMT Slide template Barcelona 7
More informationLate effects and long-term survivorship after HSCT
Late effects and long-term survivorship after HSCT André Tichelli What are late effects? Why is it of importance? How to proceed in daily routine? 59-year old male survivor 22 years after allogeneic HSCT
More informationSurvivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life
1 Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center April 16, 2016 (40 min) Hematopoietic
More informationLate effects after HSCT
Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support
More informationProtecting Your Health After Transplant (Adults)
Protecting Your Health After Transplant (Adults) Navneet Majhail, MD, MS Medical Director, Health Services Research, National Marrow Donor Program Adjunct Associate Professor of Medicine, University of
More informationSurvivorship After Stem Cell Transplantation and Long-term Followup
Survivorship After Stem Cell Transplantation and Long-term Followup Navneet Majhail, MD, MS Director, Blood & Marrow Transplant Program, Cleveland Clinic Professor, Cleveland Clinic Lerner College of Medicine
More informationLate Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor
Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Saro Armenian, DO, MPH Associate Professor, Departments of Pediatrics and Population Sciences Director,
More informationLate Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT
Objectives Late Complications Navneet Majhail, MD, MS Review late complications in hematopoietic cell transplant (HCT) recipients Review screening and prevention guidelines for HCT survivors Review upcoming
More informationLate Complications. Navneet Majhail, MD, MS
Late Complications Navneet Majhail, MD, MS Medical Director, Health Services Research, NMDP Assistant Scientific Director, CIBMTR Adjunct Associate Professor of Medicine University of Minnesota Objectives
More informationLate Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor
Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Saro Armenian, DO, MPH Associate Professor, Departments of Pediatrics and Population Sciences Director,
More informationLong-Term Outcomes After Hematopoietic Cell Transplantation
Long-Term Outcomes After Hematopoietic Cell Transplantation Conflicts of Interest No relevant financial conflicts of interest Navneet Majhail, MD, MS Medical Director, NMDP Assistant Scientific Director,
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationPERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey
PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationLate Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D.
Late Effects after Transplantation for Pediatric Severe Aplastic Anemia Jean E. Sanders, M.D. Patient Characteristics Acquired Fanconi Number 137 15 Gender F:M 63:74 9:6 Etiology: Idiopathic Hepatitis
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationOmori et al. SpringerPlus 2013, 2:424 a SpringerOpen Journal
Omori et al. SpringerPlus 2013, 2:424 a SpringerOpen Journal RESEARCH Eleven secondary cancers after hematopoietic stem cell transplantation using a total body irradiation-based regimen in 370 consecutive
More informationCoping with Pediatric Post-transplant Issues. K. Scott Baker, MD, MS Director, Pediatric Blood and Marrow Transplant and Survivorship Programs
Coping with Pediatric Post-transplant Issues K. Scott Baker, MD, MS Director, Pediatric Blood and Marrow Transplant and Survivorship Programs Risk Factors for Late Complications Pre-HCT exposures and comorbidities
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationComplications of HCT: Late Effects
Complications of HCT: Late Effects WBMT Congress 2014 Naeem A Chaudhri MD FACP King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia BMT Complications and Management Approximately 50,000
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationLate effects and quality of life after haematological stem cell transplantation
Late effects and quality of life after haematological stem cell transplantation Prof. dr hab. Ewa Gorczyńska Zofia Lutrowicz Department of Pediatric Hematology Oncology and Bone Marrow Transplantation,
More informationSURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY
SURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY Some Statistics Approximately 1 in 2 Canadians develop cancer 25% of Canadians die of cancer 2009: 810,000 Canadians
More informationLONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS
LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationPEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH
PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP Denise Rokitka, MD, MPH Objectives Describe incidence of childhood cancer and survival rates and causes of early mortality. Understand the late effects of cancer
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationEndocrine Late Effects in Survivors of Pediatric SCT
Endocrine Late Effects in Survivors of Pediatric SCT Daphna Hutt Pediatric Hem-Onc & BMT Sheba Medical Center, Israel #EBMT2015 www.ebmt.org Stiller CA (2007). Childhood Cancer In Britain. Oxford University
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationDisclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
ALL in AYAs: Health Outcomes as a Criterion for Selecting Optimal Therapy David R. Freyer, DO, MS Director, Survivorship and Supportive Care Program, Children s Center for Cancer and Blood Diseases, Children
More informationExperimental Hematology 31 (2003)
Experimental Hematology 31 (2003) 1182 1186 Busulfan-cyclophosphamide versus total body irradiation cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationCOHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationCHAPTER 12. Long term survivorship, general health status, quality of life and late complications after HSCT. A. Tichelli, C-P. Schwarze, G.
EBMT2008_1_21:EBMT2008 6-11-2008 9:17 Pagina 236 * CHAPTER 12 Long term survivorship, general health status, quality of life and late complications after HSCT A. Tichelli, C-P. Schwarze, G. Socié EBMT2008_1_21:EBMT2008
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationCauses of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt
Causes of Death J. Douglas Rizzo, MD MS February, 2012 New11_1.ppt Overview Attribution of COD important for research purposes Frequently not correctly coded or completely reported Source of confusion
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationOutline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT
Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationRIC in Allogeneic Stem Cell Transplantation
RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants
More informationLong-term effects of chronic GVHD in adults. Bipin Savani
Long-term effects of chronic GVHD in adults Bipin Savani Transplants Transplant Activity in the U.S. 14000 12000 10000 Autologous Sibling Donor HCT Unrelated Donor HCT 8000 6000 4000 2000 0 CIBMTR Summary
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationAre We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017
Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationLong Term Recovery Life After Transplantation
Long Term Recovery Life After Transplantation Long-Term Follow-Up (LTFU) Questions? LTFU@seattlecca.org 1 1/12/2018 Mission of Long-Term Follow Up To provide life-long medical consultation to hematopoietic
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationWhy? What? When? How? Dr C Fryer FRCPC) Surveillance
Why? What? When? How? Dr C Fryer FRCPC) Surveillance 1 Disclosure; Disclosure; None. I have no conflicts. I have no industry financial relationships. Background: Relapse is the single most likely late
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationShould patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?
Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Pierre Fenaux Cohem 2012 Barcelona Should patients with higher risk MDS (or AML
More informationChapter 11. Late Effects in Fanconi Anemia Patients Post-Transplant. Introduction. Overview
Chapter 11 Late Effects in Fanconi Anemia Patients Post-Transplant Margaret L. MacMillan, MD, K. Scott Baker, MD, and John E. Wagner, MD Introduction A greater proportion of FA patients are now surviving
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationCHAPTER 15 Late effects in patients treated with HSCT
* CHAPTER 15 Late effects in patients treated with HSCT André Tichelli, Gérard Socié on behalf of the Late Effects Working Party of the EBMT, with the contribution from Alicia Rovó, Jakob Passweg, Carl
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationComorbidities prior to Hematopoietic Cell Transplantation
Who is fit for transplant? Comorbidities prior to Hematopoietic Cell Transplantation Marcelo C. Pasquini, MD, MS CIBMTR Medical College of Wisconsin Outline Clinical relevance of studying risk factors
More informationG. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728
G. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728 16:00-17:30 Session 7 GvHD Prevention by T-Cell Modulation Is photopheresis treatment
More informationThe Current Pediatric Oncology Landscape
The Current Pediatric Oncology Landscape An Imperative for Change Smita Bhatia, MD, MPH UAB Department of Pediatrics at Children s Hospital of Alabama Five-year Observed Survival Rates for Two Time Periods,
More informationOutcome of patients with hematologic malignancy admitted to the ICU
Outcome of patients with hematologic malignancy admitted to the ICU Geeta Mehta MD, FRCPC Mount Sinai Hospital Toronto, Canada CCCF November 2, 2016 Disclosures Hematologic Malignancy Advances in diagnostics,
More informationOvarian function and pregnancy after Hematopoietic Stem Cell Transplant
Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Factors that influence post transplantation fertility and ovarian function in women Total body irradiation (TBI) Drugs prescribed
More informationDr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology
Advances in Autologous and Allogeneic Stem Cell Transplantation Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology April 12, 2014 Disclosures
More informationHematopoietic Stem Cell Transplantation for Fanconi Anemia
Hematopoietic Stem Cell Transplantation for Fanconi Anemia John E. Wagner, M.D. Blood and Marrow Transplant Program University of Minnesota Cell Therapy for Pediatric Diseases NHLBI PACT Workshop 14 15
More informationWest of Scotland Cancer Network. Haemato-oncology Managed Clinical Network
West of Scotland Cancer Network Haemato-oncology Managed Clinical Network Recommended Screening and Preventative Practices for Adult Long- Term Survivors after Allogeneic Haemopoietic Stem Cell Transplant
More informationADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationLatest results of sibling HSCT in acquired AA. Jakob R Passweg
Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and
More informationInfective hepatic complications in HSCT patients. Simone Cesaro. Pediatric Hematology Oncology Verona, Italy. Session II: organ specific complications
Session II: organ specific complications Infective hepatic complications in HSCT patients Simone Cesaro Pediatric Hematology Oncology Verona, Italy simone.cesaro@ospedaleuniverona.it Liver complications
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationCHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in of Childhood Leukemia with Down Syndrome Analysis Concept Proposal Working Group and Investigators Genetics Working Group & Chronic Disease Working
More informationRelapse. 2y-OS 14% Cell-based therapy in CR 2y-OS 55% X. Poiré et al. 2
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell
More information